Treatment sequencing for pancreatic neuroendocrine tumors: daring to challenge the status quo
Editorial (Pancreatic Neuroendocrine Tumors)

Treatment sequencing for pancreatic neuroendocrine tumors: daring to challenge the status quo

The incidence of pancreatic neuroendocrine tumors (pNETs) continues to increase, prompting renewed interest in the pathophysiology and treatment of this disease (1). These rare tumors are biologically distinct from pancreatic ductal carcinoma (PDAC) and account for less than 3% of pancreatic cancers. While the prognosis of patients with pNET in general is more favorable than PDAC, there is wide variation in phenotype and survival outcomes between patients. Surgical resection has been the mainstay of therapy, but recently, a plethora of clinical trials have identified novel therapies that improve symptom free survival and delay disease progression.

Treatment sequencing has been widely explored in most all solid tumors. For example, there is strong evidence for the addition of radiotherapy and chemotherapy to surgery in the treatment of localized PDAC, with many advocating for delivery of these treatments neoadjuvantly to maximize receipt of therapy and improve outcomes. However, there is little data to guide arguments for treatment sequencing in pNET, and until recently, adjuvant therapeutic options were limited. Our improved understanding of the molecular pathways involved in the tumorigenesis of pNETs has resulted in the development of novel therapies which have greatly expanded the options for treatment sequencing in patients with locally advanced and metastatic pNETs.

Therapeutic decisions surrounding the optimal sequence of treatments in patients with pNET must first be centered on the tumor. Tumor grade as defined by the World Health Organization (WHO) carries both prognostic and predictive significance (2). Both tumor differentiation and tumor proliferation are important harbingers of tumor biology. The differentiation of highly proliferative well-differentiated tumors (G3-NET) and poorly differentiated carcinomas (NEC) is an important one that has prompted debate on optimal management of these high-grade tumors (3). In general, NECs are associated with shorter recurrence-free survival and overall survival even after curative resection (3). This begs the question, would patients with NEC, even those with apparently localized disease, benefit from systemic therapy first? Could we spare those at highest risk for distant failure a non-curative resection that confers little benefit?

Knowing the extent of disease and the surgeon’s ability to provide complete tumor extirpation is also critical to achieving optimal outcomes. The development of the radiographic isotope Gallium-68 (68Ga) DOTATATE for use in positron emission tomography (PET) has significantly improved visualization of NETs. Accurate delineation of the extent of disease now allows for improved surgical planning and a more informed discussion of treatment sequencing especially in patients with metastatic or locally advanced tumors (4). 68Ga- DOTATATE PET can also allow for predicting and assessing treatment response. In addition, in patients with synchronous liver metastases where pancreatectomy would require a biliary enteric anastomosis, the order of surgical therapies may be very important. A biliary enteric anastomosis will allow bacteria access to the liver and thereby increase the risk for liver abscess after liver directed therapy (5). The implications of identifying and treating liver metastasis prior to pancreatic resection may encourage the sequencing of other therapies, including liver directed treatments and/or systemic therapy prior to surgical resection of the primary tumor in the pancreas. The role of peptide receptor radionuclide therapy (PRRT) and other targeted therapies as a neoadjuvant strategy is also being investigated (6).

While no clear guidelines exist to support the best sequence of treatments in patients with pNET, the current advances in molecular research inch towards a more personalized approach to the multimodality therapy of pNETs. This focused series comprehensively reviews the pathophysiology, tumorigenesis, available clinical trials, and approved therapies for patients with pNETs. A deeper understanding of these factors is necessary to enhance our efforts to improve patient improve patient outcomes through the application of more innovative treatment sequencing. While patients with a localized, resectable tumor may go straight to surgery, those with locally advanced or synchronous metastatic disease may benefit from the delivery of a more complicated series of treatments which are somewhat personalized to the patient and the molecular/proliferative profile of their tumor.


Acknowledgments

Funding: None.


Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Journal of Gastrointestinal Oncology for the series “Pancreatic Neuroendocrine Tumors”. The article did not undergo external peer review.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jgo-2019-pnt-07). The series “Pancreatic Neuroendocrine Tumors” was commissioned by the editorial office without any funding or sponsorship. CNC and DBE served as the unpaid Guest Editors of the series. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.


References

  1. Howlader N, Noone AM, Krapcho M, et al. editors. SEER Cancer Statistics Review, 1975-2017. Bethesda: National Cancer Institute. Available online: https://seer.cancer.gov/csr/1975_2017/, based on November 2019 SEER data submission, posted to the SEER web site, April 2020.
  2. Lloyd RV, Klöppel G, Rosai J. editors. WHO classification of tumours of endocrine organs. 4th ed. Lyon: IARC Press, 2017.
  3. Basturk O, Yang Z, Tang LH, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol 2015;39:683-90. [Crossref] [PubMed]
  4. Has Simsek D, Kuyumcu S, Turkmen C, et al. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors? J Nucl Med 2014;55:1811-7. [Crossref] [PubMed]
  5. De Jong MC, Farnell MB, Sclabas G, et al. Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis. Ann Surg 2010;252:142-8. [Crossref] [PubMed]
  6. van Vliet EI, van Eijck CH, de Krijger RR, et al. Neoadjuvant treatment of nonfunctioning pancreatic neuroendocrine tumors with [177Lu-DOTA0,Tyr3]Octreotate. J Nucl Med 2015;56:1647-53. [Crossref] [PubMed]
Callisia N. Clarke
Douglas B. Evans

Callisia N. Clarke1, MD, MS, FACS

1Assistant Professor of Surgery, Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
(Email: cnclarke@mcw.edu)

Douglas B. Evans2, MD, FACS

2Chair, Department of Surgery, Donald C. Ausman Family Foundation Chair, Medical College of Wisconsin, Wauwatosa, WI, USA.
(Email: devans@mcw.edu)

Submitted Mar 26, 2020. Accepted for publication Jun 08, 2020.

doi: 10.21037/jgo-2019-pnt-07

Cite this article as: Clarke CN, Evans DB. Treatment sequencing for pancreatic neuroendocrine tumors: daring to challenge the status quo. J Gastrointest Oncol 2020;11(3):545-547. doi: 10.21037/jgo-2019-pnt-07